Pharma Marketletter articles from October 2005

Pharma Marketletter archives from October 2005

Galapagos picks up UK's BioFocus for L20M.(Brief Article)
October 3, 2005... Dutch genomics-based group Galapagos NV has made an agreed all-share offer of some L20.2 million ($36.4 million) for UK biotechnology firm BioFocus. The bid price represents a premium of around 121% on the UK firm's closing price of 56.0 pence...

Plans for Namibian pharma company.(Brief Article)
October 3, 2005... The government of Namibia is proposing to raise Namibian $80.0 million ($12.4 million) to start up a pharmaceutical plant, according to Cabinet documents seen by the local newspaper, The Namibian. The venture will be channelled through Meduletu...

Mayne proceeds with demerger plan.(Mayne Group Ltd.)(Brief Article)
October 3, 2005... Australian drugmaker Mayne Group is moving ahead with previously-announced demerger plans, and has lodged an Explanatory Memorandum for the separation of its injectable generic and specialty pharmaceutical businesses with the Australian...

Nasdaq listing for UK's Protherics.(Brief Article)
October 3, 2005... UK biopharmaceutical company Protherics says it has received preliminary approval from the USA's Nasdaq Stock market to establish a Level II American Depositary Receipt program in the USA.

Transgenomic makes $15M placing.(Brief Article)
October 3, 2005... Transgenomic says that it has received commitments from a group of institutional investors led by Lehman Brothers to purchase 15 million shares of its common stock through a private placement priced at $1.01 per share. Net proceeds will be used...

Pfizer debuts Lyrica in the USA.(Brief Article)
October 3, 2005... World leading pharmaceutical company Pfizer has now launched Lyrica (pregabalin) in the USA. The drug, which debuted in Europe last year, is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy,...

Stiefel licenses Uriach drug albaconazole.(Stiefel Laboratories and Grupo Uriach)(Brief Article)
October 3, 2005... Spain's Grupo Uriach has licensed its developmental drug albaconazole (UR-9825), an oral, broad-spectrum antifungal that has shown a promising clinical profile in Phase II trials, to privately-held US dermatological firm Stiefel Laboratories....

Amarin starts Ph III Miraxion enrollment.(Brief Article)
October 3, 2005... UK-based Amarin Corp says that patient enrollment and first dosing have commenced in its US Phase III clinical trial of Miraxion (ultra-pure ethyl-eicosapentaenoic acid) in Huntington's disease. The primary endpoint of the study will be to...

Roche/OSI's Tarceva debuts in UK.(Brief Article)
October 3, 2005... Following swiftly on its approval by the European Commission (Marketletter September 26), Roche's Tarceva (erlotinib) was launched in the UK on September 22. The price to the UK National Health Service for one month's treatment will be L1,631...

Favorable EU opinion for Nabi's Altastaph.(Brief Article)
October 3, 2005... Nabi Biopharmaceuticals says that it has received a favorable opinion in the Europe Union regarding Orphan Medicinal Product designation for Altastaph (human Staphylococcus aureus immunoglobulin) for the treatment of S aureus bacteremia. ...

AEterna initiates Ph II trial with perifosine in NSCLC.(non-small cell lung cancer)(Brief Article)
October 3, 2005... Canada's AEterna Zentaris has announced the initiation of a European multicenter, Phase II trial of perifosine, a novel, first-in-class, oral signal transduction inhibitor, in combination with radiotherapy, in non-small cell lung cancer. This...

Memory Pharma makes $31M placing.(Memory Pharmaceuticals Corp.)(Brief Article)
October 3, 2005... New Jersey, USA-based Memory Pharmaceuticals says that it has entered into a definitive purchase agreement for a private placement of an aggregate of approximately 16.1 million newly-issued shares of common stock, at a price of $1.90 each, to...

Myogen completes $125M financing.(Brief Article)
October 3, 2005... US firm Myogen says it has completed its previously-announced underwritten public offering of 4,675,082 shares of newly-issued common stock and the exercise by the underwriters of their over-allotment option to purchase an additional 701,262...

EMEA plans speedier scientific advice process.(European Medicines Agency)(Brief Article)
October 3, 2005... The European Medicines Agency (EMEA) has launched a two-month public consultation exercise on improvements which it proposes to make in the way it provides scientific advice on R&D of new medicines. The main features of the revised...

Personalized medicine "still decades away," says UK Royal Society report.
October 3, 2005... Personalized medicine, or pharmacogenetics, has a promising future but it will be another 15-20 years before its use is widespread, due to the many gaps in understanding of how genetics relates to the causes of disease, says a new report...

Biotech group calls on EU for more patient-oriented approach to health care.(EuropaBio)
October 3, 2005... EuropaBio, the European bioindustries' association, has set out what it sees as the key policies needed to enable the health care innovations which are expected in the next few years to address unmet medical needs. The group's "manifesto"...

Spanish govt/pharma clash again over Rx law.(Brief Article)
October 3, 2005... Farmaindustria, Spain's major drug industry association, has again attacked the government's proposed new health care law. The bill seeks to curb Spain's soaring drugs bill, which rose 9% in August from July to 783.6 million euros ($952.4...

Pharma to gain $139B from US Rx benefit?(medicare prescription drug benefit)
October 3, 2005... The pharmaceutical industry could reap as much as an extra $139.00 billion as a result of the new US Medicare prescription drug benefit, according to data published in the Philadelphia Inquirer daily newspaper. The program could be a boon...

US physicians strongly back DTC policing: study.(direct-to-consumer advertising)
October 3, 2005... As drugmakers in the USA attempt to determine appropriate protocols for direct-to-consumer advertising of their new prescription medications (Marketletters passim), 81% of 2,015 physicians questioned for a new survey said it is a good idea to...

Vernalis reports widening losses.(Brief Article)
October 3, 2005... UK-based biotechnology firm Vernalis has reported that interim losses rose to L19.4 million ($34.7 million) for the six-month period ended June 30, 2005. The financial results are the first the group has prepared in accordance with...

Alizyme's half-year losses rise L9.3M.(Brief Article)
October 3, 2005... Alizyme, a Cambridge, UK-headquartered drugmaker, says that its half-year 2005 losses,which have risen to L10.7 million ($19.1 million) from L1.1 million in 2004, are due to an increase in R&D investment. The firm has yet to report any...

RNAx and Nucleis to co-market shRNA validation technology.(Brief Article)
October 3, 2005... French biotechnology firm Nucleis and validation technology development group RNAx, headquartered in Berlin, Germany, have signed a non-exclusive agreement covering the marketing of in vitro and in vivo versions of shRNA validation technology....

Oxigene's CA4P to enter Ph II trial.(combretastatin A4 phosphate)(Brief Article)
October 3, 2005... USA-based drugmaker Oxigene says that it has completed a significant stage in the development of its lead vascular-disrupting agent combretastatin A4 phosphate. The firm says it is initiating a Phase II trial designed to evaluate the drug's...

BioSant welcomes FDA approval of Pfizer's Exubera.
October 3, 2005... Illinois, USA-based BioSante Pharmaceuticals says that the Food and Drug Administration Advisory Panel's recommendation forapproval of Pfizer's Exubera, an inhaled insulin therapy for diabetics, is an encouraging development (Marketletter June...

Study reveals Procrit superior to Aranesp in anemia treatment.(Brief Article)
October 3, 2005... A study, published in the September issue of the Oncologist magazine, showed that Johnson & Johnson's drug Procrit (epoetin alfa) was superior to Amgen's Aranesp (darbepoetin alpha), in increasing hemoglobin levels in patients with anemia...

Barrier retains world rights to Hyphanox.(Brief Article)
October 3, 2005... Dermatology specialist drugmaker Barrier Therapeutics will retain worldwide rights for all licensed indications to its oral antifungal product candidate Hyphanox (itraconazole). Janssen Pharmaceutica Products held an option for the rights to...

Neurogen's NG2-73 "safe and well-tolerated".(Brief Article)
October 3, 2005... US drugmaker Neurogen has completed the first-in-human, single ascending-dose study of its lead drug candidate for insomnia, NG2-73, which selectively modulates receptors of the gamma-aminobutyric acid neurotransmitter system. In this...

Savient petititons FDA to extend Oxandrin exclusivity.(Brief Article)
October 3, 2005... Savient Pharmaceuticals, an emerging USA-based specialty drugmaker, has filed a Citizens' Petition with the Food and Drug Administration requesting that it deny approval for any Abbreviated New Drug Applications for generic oral products...

Vernalis signs manufacturing contract with Diosynth.(Diosynth Biotechnology)(Brief Article)
October 3, 2005... UK drugmaker Vernalis has signed a contract with Diosynth Biotechnology for process development, scale-up and manufacturing of the former's novel thrombolytic V10153 for Phase III clinical trials. The agreement will see Vernalis transfer...

Crawford departs abruptly from US FDA.(Lester Crawford)
October 3, 2005... Lester Crawford resigned as Commissioner of the US Food and Drug Administration on September 23, with immediate effect, in a move which took agency staff and observers entirely by surprise. On the same day, President George W Bush announced...

Medicare: Under $20 Rx plans in 49 US states.(Brief Article)
October 3, 2005... Medicare has now formally approved prescription drug plans and Medicare Advantage schemes which will offer such coverage starting January 1, 2006. The prescription drug plans, which will work with traditional Medicare, and the Medicare...

Vermont Rx import law suit dismissed.(Brief Article)
October 3, 2005... The US government acted legally by refusing to allow the state of Vermont to import prescription drugs for its employees, a District Court judge has ruled, overturning the state's 2004 claim that the Food and Drug Administration was responsible...

Defending Rx revenue through new combos.
October 3, 2005... The pharmaceutical industry has experienced a recent surge in the development of new combination therapies, a lifecycle management tactic which is an effective way to offset declines in particular products' market share, says a new study from...

On-line activity fuels surging US Rx drug abuse.(Brief Article)
October 3, 2005... The most recent US National Survey on Drug Use and Health has found that about 6% of young adults used prescription drugs non-medically in the past month, and 29% had done so in their lifetime. An estimated 7.5 million were currently using...

Ardana says Teverelix may be released early.(Brief Article)
October 3, 2005... Ardana, a pharmaceutical firm based in Edinburgh, Scotland, says that the launch of its lead development compound Teverelix Long-Acting, a gonadotropin- releasing hormone antagonist intended for use in the treatment of benign prostatic...

AstraZeneca submits NDA for Symbicort.(new drug application)(Brief Article)
October 3, 2005... Anglo-Swedish drug major AstraZeneca says it has submitted a New Drug Application to the US Food and Drug Administration for the approval of Symbicort (budesonide /formoterol) for the maintenance treatment of asthma . The NDA is based on...

Napp Pharma debuts new OA treatment.(oral analgesics)(Brief Article)
October 3, 2005... UK drugmaker Napp Pharmaceuticals, headquartered in Cambridge, says it has launched a new seven-day patch, marketed as BuTrans (buprenorphine) for use in the treatment of osteoarthritic pain. The product is available at 5mg, 10mg and 20mg...

AstraZeneca reports positive Zomig trials.(Brief Article)
October 3, 2005... In an address to the European Federation of Neurological Societies congress, held in Athens, Greece, pharmaceutical major AstraZeneca presented the conclusions of recent studies of its headache treatment Zomig (zolmitriptan). The trial data...

ReNeuron seeks FDA approval for ReN001.(ReNeuron Holdings PLC)(Brief Article)
October 3, 2005... UK-based stem cell development firm ReNeuron has announced the completion of pre-Investigational New Drug talks with the US Food and Drug Administration regarding its stroke therapy ReN001. The group met in July with members of the FDA's Center...

Clinical trial participants: "not unrepresentative," says study.(Brief Article)
October 3, 2005... It is often suggested that the results of clinical trials are unrepresentative, in that study participants are likelier to comply with their medication than those in standard care. However, this assumption is challenged by new data presented at...

Yeast shows potential as a nasal penetration enhancer.(Brief Article)
October 3, 2005... Traditionally, yeast has been used for making beer and bread but researchers in the UK have found that it may be important in the nasal delivery of insulin. Emily Fuller, a researcher at the School of Biochemistry and Microbiology at Leeds...

DiaGenic wins IPA award for potential AD diagnostic.(International Psychogeriatric Association, Alzheimer's disease )(Brief Article)
October 3, 2005... Norwegian life sciences company DiaGenic ASA was awarded first place for its poster presentation Detection of Alzheimer's disease based on gene expression patterns in peripheral blood cells at the International Psychogeriatric Association's...

Rohm and Haas begins own distribution network.(Brief Article)
October 3, 2005... The Advanced Biosciences division of US specialty materials maker Rohm and Haas says that its complete range of solutions for the production of biopharmaceuticals will now be sold directly to customers. To better serve both existing...

Genzyme opens UK R&D center as part of $540 million European expansion.
October 3, 2005... Last week, US biotechnology major Genzyme opened four European facilities as part of a milestone investment eventually expected to cost $540.0 million. The expansion includes a drug discovery research facility in Cambridge, UK, that will employ...

$37.5M expansion for GE's Shanghai plant.
October 3, 2005... GE Healthcare, a unit of the USA's General Electric Co, will spend $37.5 million to extend its production facility in Shanghai, the People's Republic of China, in order to meet increasing customer demand for its products in the domestic market...

Letter to the Editor on generics in Europe.(Letter to the Editor)
October 3, 2005... Letter to the Editor Dear Sir, I read with great interest your article "AstraZeneca's McKillop lashes out at Europe's neglect of pharma industry" (September 19, 2005). I regret that there are some factual errors in the piece. I...

Qiagen buys Chinese biotech in $14.5M deal.(Shenzhem PG Biotech)
October 3, 2005... Dutch firm Qiagen NV says it has entered into an agreement to purchase all the outstanding shares of Shenzhem PG Biotech, based in Shenzhem, China, which it describes as "a leading developer, manufacturer and supplier of polymerase chain...

Ranbaxy sets up operation in Canada, promising to shake up drug distribution.
October 3, 2005... India's largest drugmaker, Ranbaxy Laboratories, has announced its entry into the Canadian health care system, saying it will use its large portfolio of generic drugs to shake up the sales and distribution of medicines in that country. The new...

New Live Scientific in deal with Cure Lab.(Brief Article)
October 3, 2005... New Life Scientific has announced the signing of a letter of intent with fellow US company CureLab for a long-term joint development and marketing plan for the latter's pharmaceutical and biotechnology products. Wall Street Capital Funding saw...

Corgentech and AlgoRx announce merger.(Brief Article)
October 3, 2005... US firms Corgentech and AlgoRx Pharmaceuticals have entered into a definitive, all-share, merger accord to create a late-stage company with "a deep pipeline of clinical products that will be largely focused on developing and commercializing...

Genentech shares fall after it stops trial of Avastin in ovarian cancer.
October 3, 2005... US biotechnology giant Genentech saw its share price tumble 3.8% to $84.66 in morning trading on September 23, after the firm announced that enrollment into a multicenter, single-arm Phase II study of Avastin (bevacizumab) in...

Isotechnika's ISA247 meets primary and secondary endpoints in Ph III.(Brief Article)
October 3, 2005... Canadian biopharmaceutical firm Isotechnika has unblinded 12-week data for its Phase III psoriasis trial of its lead immunosuppressive agent ISA247, which showed that the drug met all primary and secondary efficacy endpoints. The news sent the...

From blockbuster drugs to nichebuster products - by Gilbert Mertens.
October 3, 2005... The "blockbuster phenomenon" is essentially an American situation: the global sales of these drugs are generated mainly in the USA. They range between 67% and 86% of sales of companies that follow this model (with sales levels the industry...

OctoPlus and Singvax to develop JE drug.(Japanese encephalitis)(Brief Article)
October 3, 2005... Dutch drug developer Octoplus and Singapore-based vaccine development company SingVax have announced that they are to jointly develop a single-shot Japanese encephalitis vaccine. The firms say that they wish to develop a product that ensures...

Alnylam licenses RNAi technology to Qiagen.
October 3, 2005... Alnylam Pharmaceuticals, headquartered in Cambridge, Massachusetts, USA, says that it has granted Qiagen NV, a Dutch firm specializing in DNA sequencing and genetic research tools, a non-exclusive license to provide research products and...

Marc's drug slows tumor growth in mice.(Brief Article)
October 3, 2005... USA-based Marc Pharmaceuticals says that one of its leading drug candidates, a betulinol-derived compound, has slowed the rate of prostate tumor growth in recent animal studies carried out for the company at Stamford University in Connecticut....

ELI Lilly publishes Evista study data.(Brief Article)
October 3, 2005... USA-based drug major Eli Lilly has published the results of eight years of trials of its osteoporosis drug Evista (raloxifene HCL) in the September issue of Current Medical Research and Opinion. The compound is the only selective estrogen...

MedImmune enters oncology R&D accord.(Brief Article)
October 3, 2005... Maryland, USA-headquartered pharmaceutical group MedImmune has entered into a licensing and collaboration agreement with Georgetown University for the development of monoclonal antibodies targeting anaplastic lymphoma kinase, a member of the...

VIVUS' HSDD spray closer to Ph III.(hypoactive sexual desire disorder)(Brief Article)
October 3, 2005... USA-based drugmaker VIVUS says it has had a useful meeting with the US Food and Drug Administration regarding Testosterone MDTS, its metered-dose transdermal spray for the treatment of hypoactive sexual desire disorder. VIVUS disclosed...

Abmaxis and MaimoniDex enter RA MAb R&D accord.(Brief Article)
October 3, 2005... Abmaxis, a privately-held US biopharmaceutical firm, and MaimoniDex RA, an Israeli biotechnology company focused on the treatment of rheumatoid arthritis, have signed an agreement to jointly develop a therapeutic human monoclonal antibody for...

Neurologix' AAV for PD sees good Ph I results.(associated viral vector for Parkinson's disease)(Brief Article)
October 3, 2005... US drugmaker Neurologix has reported positive interim results from a landmark gene therapy clinical trial using a non-pathogenic adeno-associated viral vector for patients with Parkinson's disease. The 12-patient, dose-escalating Phase I...

Geneservice and RZPD to distribute DNABook.(Kabushiki Kaisha Dnaform)(Brief Article)
October 3, 2005... Cambridge, UK-based genomic research specialist Geneservice and the RZPD German Resource Center for Genome Research have entered into an agreement with Japan's Kabushiki Kaisha Dnaform for the distribution of the Mouse Genome Encyclopaedia...

MIP's Zemiva passes proof-of-concept stage.(Molecular Insight Pharmaceuticals)(Brief Article)
October 3, 2005... The USA's Molecular Insight Pharmaceuticals says that recent Phase IIa study data demonstrate that its lead molecular imaging candidate, Zemiva (iodofiltic acid I 123), can detect areas of decreased fatty acid metabolism at rest that parallel...

Japan stock market week to Sept 26.
October 3, 2005... Tokyo saw an accelerated advance in the week to September 26 (four trading days because September 23 was a national holiday in Japan). The Nikkei 225 rose 3.3%, closing the review week at the 13,300 mark for the first time since June 8, 2001,...

Biomira delays BLP25 vaccine trial.(Brief Article)
October 3, 2005... Canada's Biomira has announced a change to the anticipated timetable for the start of its planned BLP25 liposome vaccine Phase III study in the treatment of non-small cell lung cancer. It says that the change will allow the company and its...

Genzyme debuts exclusive lung cancer test.(EGFR Mutation Assay )(Brief Article)
October 3, 2005... US biotechnology group has announced the commercial availability of a new laboratory test to help identify patients likely to respond to therapies targeted for the treatment of non-small cell lung cancer). The firm's EGFR Mutation Assay will...

FDA accepts King Pharma's sNDA for Altace.(Food and Drug Administration)(supplemental new drug application)(Brief Article)
October 3, 2005... The US Food and Drug Administration has accepted for filing King Pharmaceuticals' supplemental new drug application seeking a new indication for Altace (ramipril), its angiotensin-converting enzyme inhibitor. Specifically, King is asking for...

Novo Nordisk sues Sanofi over OptiClik.(Brief Article)
October 3, 2005... Denmark's Novo Nordisk says it has filed a patent infringement law suit against French drug major Sanofi-Aventis claiming that its OptiClik insulin pen system infringes a Novo Nordisk US patent relating to its FlexPen insulin delivery device....

Biogen Idec/Elan submit sBLA for Tysabri with the FDA, European filing to follow.(Food and Drug Administration)(Elan Corp.)
October 3, 2005... As has been expected, US biotechnology firm Biogen Idec and Ireland-based Elan Corp have submitted a supplemental Biologics License application for their withdrawn multiple sclerosis drug Tysabri (natalizumab) with the US Food and Drug...

Roche/GSK to test Bonviva vs Fosamax.
October 3, 2005... Leading pharmaceutical groups Roche of Switzerland and GlaxoSmithKline of the UK have initiated a large-scale, head-to-head clinical trial which, for the first time, will compare their new once-a-month osteoporosis drug Bonviva (ibandronate...

Patent reform and generic biologics not now top of US agenda, Hatch tells industry.
October 3, 2005... Addressing a policy meeting of the US Generic Pharmaceutical Association, Senator Orrin Hatch and Representative Henry Waxman disagreed over whether the 1984 Act bearing their names permits the sale of authorized or licensed generics. They...

Crawford "step-aside" preposterous, says NYT.(Lester Crawford criticized)(Brief Article)
October 3, 2005... US Food and Drug Administration Lester Crawford's stated reason for his shock resignation - that, at age 67, it is time for him to step aside (see page 13) - is preposterous, according to an editorial in the New York Times. The...

Indian Rx sector "set to grow 11% by 2007-8".(Brief Article)
October 3, 2005... India's pharmaceutical industry is expected to grow around 11% to reach a value of 600.00 billion rupees ($13.64 billion) in the year to March 31, 2008, from the current official estimate of 390.00 billion rupees for 2003-4, says ASSOCHAM, the...

UAE to fix pharma prices against US$.(Brief Article)
October 3, 2005... From 2006, drug prices in the United Arab Emirates are to be fixed against the US dollar, in an attempt to stabilize them, the Ministry of Health has said. Currently, prices are fixed against a range of currencies depending on the products'...

Canada: out-of-pocket Rx spend +71% in 10 years.
October 3, 2005... In Canada, household spending on prescription drugs jumped more than 70% during 1992-2002 and, while out-of-pocket spending on medications represented less than 1% of the family budget by 2002, it had surged 71% during the decade, says new data...

Gulf states agree to monitor bio drugs.(Brief Article)
October 3, 2005... Arab Gulf Cooperation Council member states have agreed to step up their surveillance of new biotechnology-based medicines due to high demand for these products, especially vaccines and blood derivatives. The group has also reviewed its...

TopoT/Curagen's PXD101 Ph Ib trial starts dosing.(TopoTarget AS)(Brief Article)
October 3, 2005... Danish drugmaker TopoTarget AS and the USA's CuraGen have inititated patient dosing in a Phase Ib open-label, multi-center, proof-of-concept clinical trial evaluating PXD101, a small-molecule histone deacetylase inhibitor, for the treatment of...

Cogentix files patent for CGX-1160.(Brief Article)
October 3, 2005... US privately-held neurological drug research firm Cognetix has identified the novel mechanism of action for CGX-1160, its lead compound in clinical development for the treatment of chronic intractable pain. Knock-out mice were used to...

Taro gets FDA OK for generic Bactroban.(Food and Drug Administration )(Brief Article)
October 3, 2005... The USA's Taro Pharmaceutical Industries has received approval from the Food and Drug Administration for its Abbreviated New Drug Application for Mupirocin Ointment USP, 2%, the generic equivalent of UK drug major GlaxoSmithKline's Bactroban...

Watson licenses Cordran and Monodox to Aqua.(Aqua Pharmaceuticals )(Brief Article)
October 3, 2005... Aqua Pharmaceuticals has entered into a domestic licensing agreement with US specialty drugmaker Watson Pharmaceuticals to market Cordran (flurandrenolide USP), a family of topical steroids and the antibiotic Monodox (doxycycline monohydrate)...

GSK and Cytokinetics amend R&D accord.(GlaxoSmithKline)(Brief Article)
October 3, 2005... US drugmaker Cytokinetics has amended its alliance with UK drug major GlaxoSmithKline, providing the former with an expanded role in the clinical R&D for SB-743921, a novel, small-molecule inhibitor of kinesin spindle protein, developed as part...

Expanded indication for Pfizer's Lipitor.(Brief Article)
October 3, 2005... World drugs giant Pfizer's cholesterol-lowering medicine Lipitor (atorvastatin) has been approved by the US Food and Drug Administration to reduce the risk of stroke and heart attack in people with type 2 diabetes without evidence of heart...

GW's Sativex sees strong efficacy in MS pain.(GW Pharmaceuticals, multiple sclerosis)(Brief Article)
October 3, 2005... UK phytochemical drugmaker GW Pharmaceuticals says that its cannabis-based drug Sativex has been found effective in reducing central neuropathic pain and sleep disturbance in people with multiple sclerosis, in a study published in the October...

DOV/Merck & Co's DOV 216,303: strong Ph II data.(DOV Pharmaceutical, drugs for the treatment of depression)(Brief Article)
October 3, 2005... The USA's DOV Pharmaceutical has reported promising results from a Phase II clinical trial of DOV 216,303, for the treatment of depression. Last year, DOV sub-licensed the compound to US drug major Merck & Co for the treatment of depression,...